09 August 2018
Visiongain has launched a new pharma report Global Next Generation Multi-Purpose Biosensors Market 2017-2027 : Nanomechanical, Optical, Electrochemical, Thermistor/Calorimetric, Patient Monitoring, Diagnostics, Therapeutics, Wearable, Implantable, Strip, Hospitals & Clinics, Home Diagnostics, Diagnostic Centres, Research Laboratories
Over the years, the next-generation multi-purpose biosensors market has witnessed a high adoption rate for advanced biosensors. This is due to the technological breakthroughs in the biosensors field such as the development of molecular markers, nanotechnology, microfluidics, and others. Moreover, the growing demand for cost-efficient, disposable and user-friendly devices has provided momentum for the growth of the next generation multi-purpose biosensors market.
The lead analyst of the report commented “The need for better diagnosis and treatment as well as the need to curb the cost of healthcare have led to the advent of next-generation multi-purpose biosensors. The advancements in nano and micro fabrication techniques have increased the use of next generation multi-purpose biosensors in healthcare. With features such as low cost, easy to use, and accurate results, these medical biosensors are the preferred options among patients and healthcare professionals. Therefore, many key players are involved in the development and commercialization of next generation multi-purpose biosensors.”
Leading companies featured in the report include Koninklijke Philips N.V., Abbott Laboratories, Universal Biosensors Inc., Bayer Healthcare AG, GE Healthcare, Biosensors International Group. Ltd., Medtronic plc, Nova Biomedical Corporation, Bio-Rad Laboratories Inc. and Sphere Medical Holding plc
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.